PROTACs
PROTAC (PROteolysis-TArgeting Chimera) is a heterobifunctional nanomolecule containing two different ligands, ligand for ubiquitin E3 and ligand for target protein. The two parts are connected by linker to form a "three-unit" polymer, target protein ligand-linker-E3 ligase ligand. Building blocks of PROTAC molecules include PROTAC Linker, Ligand for Target Protein for PROTAC, Ligand for E3 Ligase, E3 Ligase Ligand-Linker Conjugate, Target Protein Ligand-Linker Conjugate, etc.
PROTACs Isoform Specific Products
-
PROTACs Related Products (1375)
Related Products (1375)
-
Antibodies (1)
-
PROTACs Isoform Comparison
-
PROTAC ER Degrader-15
0 ImagesCat. No.: HY-170332PROTAC ER Degrader-15 (Compound 40) is an orally active degrader of the estrogen receptor (ER) with anticancer activity，which can be used in breast cancer research (Pink: Target Protein Ligand (HY-170334); Black: Linker (HY-30756); Blue: E3 Ligase Ligand (HY-138793); E3 Ligase Ligand-Linker Conjugate (HY-169979)).
-
PROTAC ER Degrader-16
0 ImagesCat. No.: HY-183804CAS No.: 2847829-86-9
-
PROTAC ERα Degrader-10
0 ImagesCat. No.: HY-170336CAS No.: 2421260-43-5PROTAC ERα Degrader-10 is an orally active estrogen receptor α (ERα) PROTAC degrader, with DC50 values of 0.37, 1.1, and 0.47 nM in MCF7, T47D, and CAMA-1 cells, respectively. PROTAC ERα Degrader-10 exhibits significant anti-tumor activity both in vitro and in vivo, and can be used for breast cancer research.
-
PROTAC AURKA degrader 1
0 ImagesCat. No.: HY-175830PROTAC AURKA degrader 1 is a AURKA PROTAC degrader. PROTAC AURKA degrader 1 forms a ternary complex with AURKA and CRBN E3 ligase, labels AURKA to induce its ubiquitination, and promotes its degradation via the ubiquitin-proteasome system. PROTAC AURKA degrader 1 is applicable to leukemia-related research.
-
PROTAC BRD4 Degrader-6
0 ImagesCat. No.: HY-131203CAS No.: 2410947-56-5PROTAC BRD4 Degrader-6 (compound 32a) is a potent small-molecule BRD4PROTAC degrader with IC50 value of 2.7 nM for BRD4 BD1. PROTAC BRD4 Degrader-6 potently degrades BRD4 protein and inhibits the expression of c-Myc. PROTAC BRD4 Degrader-6 inhibits the proliferation of pancreatic cancer cell line BxPC3 and induces apoptosis. PROTAC BRD4 Degrader-6 can be used for human pancreatic cancer research.
-
PS21M
0 ImagesCat. No.: HY-174248PS21M is a negative control PROTAC degrader derived from CPS-021, as well as an inhibitor of ternary complex formation. PS21M attenuates the interaction with Cereblon ligase, restricting the formation of the PAK4-PROTAC-Cereblon ternary complex and the subsequent degradation of PAK4. PS21M serves as a negative control molecule to verify the degradation mechanism of CPS-021.
-
PROTAC FGFR1 degrader-1
0 ImagesCat. No.: HY-170869PROTAC FGFR1 degrader-1 is a PROTAC degrader targeting fibroblast growth factor receptor 1 (FGFR1), with a DC50 of 39.78 nM and an IC50 of 26.81 nM in KG1a cells. PROTAC FGFR1 degrader-1 selectively degrades FGFR1 via the ubiquitin-proteasome system, showing concentration- and time-dependent degradation in cancer cells. PROTAC FGFR1 degrader-1 can be used in studies related to leukemia and breast cancer.
-
PROTAC HDAC6 degrader 12
0 ImagesCat. No.: HY-123971CAS No.: 2235382-05-3
-
PROTAC CDK6 Degrader 2
0 ImagesCat. No.: HY-180262PROTAC CDK6 Degrader 2 (compound 48b), the active form of PROTAC CDK6 Degrader 1 (HY-180277), is a potent and selective PROTAC CDK6 degrader that binds strongly to KLHDC2 (KD = 0.005 μM). PROTAC CDK6 Degrader 2 functions through a KLHDC2-dependent and ubiquitin-proteasome-mediated mechanism. PROTAC CDK6 Degrader 2 can be used for cancer research.
-
PROTAC EZH2 Degrader-35
0 ImagesCat. No.: HY-181392CAS No.: 3034875-56-1PROTAC EZH2 Degrader-35 (compound U3i (44)) is a PROTAC protein degrader targeting EZH2 with a human EZH2 Ka of 16.19 nM. PROTAC EZH2 Degrader-35 exhibits antiproliferative activity in triple-negative breast cancer cells and minimal cytotoxicity in normal human epithelial, hepatic, renal cells.PROTAC EZH2 Degrader-35 can be used for the research of triple-negative breast cancer.
-
SelDeg51
0 ImagesCat. No.: HY-181289CAS No.: 3036372-80-9SelDeg51 is a selective FKBP51 PROTAC degrader with a Kd value of 18 nM and a Dmax of 90%. SelDeg51 induces proteasomal degradation of FKBP51 via the FKBP51:SelDeg51:VCB ternary complex and reactivates the glucocorticoid receptor signaling pathway. SelDeg51 can be used for research on stress-related mental disorders, chronic pain, and obesity.
-
JPS004
0 ImagesCat. No.: HY-176904CAS No.: 2559747-12-3JPS004 is a PROTAC degrader targeting HDAC1, HDAC2 and HDAC3. JPS004 induces extensive transcriptomic changes in human colon cancer cell line HCT116, including downregulation of HDAC complex components and cell cycle regulatory machinery, modulation of the AKT/mTOR signaling pathway, and upregulation of FOXO-mediated apoptosis and autophagy related genes. JPS004 can be used in colon cancer-related research.
-
PROTAC BET Degrader-17
0 ImagesCat. No.: HY-181869CAS No.: 2409674-38-8PROTAC BET Degrader-17 is a potent BET protein PROTAC degrader. By recruiting the VHL E3 ligase, PROTAC BET Degrader-17 specifically degrades BRD2, BRD3 (DC50=0.09 nM) and BRD4 (IC50=4.3 nM). PROTAC BET Degrader-17 exhibits strong anti-tumor activity in acute myeloid leukemia (AML) studies; it not only inhibits cancer cell proliferation, induces cell cycle arrest and apoptosis, but also effectively suppresses tumor growth in xenograft mouse models. PROTAC BET Degrader-17 can be used to explore targeted therapies for acute myeloid leukemia.
-
PROTAC BRD4 Degrader-16
0 ImagesCat. No.: HY-143327CAS No.: 2585561-36-8PROTAC BRD4 Degrader-16 is a BRD4 PROTAC degrader. PROTAC BRD4 Degrader-16 induces sustained degradation of both long and short isoforms of BRD4 in cancer cells, causes cell cycle arrest, and exhibits only extremely low apoptosis effects. PROTAC BRD4 Degrader-16 can be used in studies related to acute myeloid leukemia.
-
PROTAC ER Degrader-12
0 ImagesCat. No.: HY-160264PROTAC ER Degrader-12 (Compound 70) is an estrogen receptor PROTAC degrader (DC50: <10 nM), and inhibits MCF-7 proliferation (DC50: <10 nM). PROTAC ER Degrader-12 has anticancer effect.
